Becton Dickinson & Co. (BDX) Company Profile & Statistics

Becton Dickinson & Co.
BDX
(NYSE)
N/A
230.46
-3.37 (-1.44%)
in:usd•As of: Apr 25, 2024 15:59 UTC -4
Open
234.35
High
234.35
Low
230.42

About Becton Dickinson & Co.

CEO

Thomas E. Polen

Headquarters

1 becton drive

franklin lakes, nj 07417, united states

Auditor

Ernst & Young LLP

Employees

73,000

Share Holders

10,775

Website

www.bd.com

Industry

medical specialties

Sector

health technology

Company Overview

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.

Becton Dickinson & Co. Statistics

Valuation Measures

Market Capitalization ²	66.58B
Enterprise Value	81.46B
Enterprise Value/EBITDA (ttm)	19.19
Price to Earnings Ratio (ttm)	19.66
Price to Book (mrq)	2.67
Price to Sales (ttm)	3.47
Price to Cash (ytd)	11.59

Profitability

Gross Margin (ttm)	41.49%
Operating Margin (ttm)	17.89%
Profit Margin (ttm)	6.30%
Return on Equity (ttm)	13.57%
Return on Invested Capital (ttm)	3.19%
Return on Assets (ttm)	6.56%

Income Statement

Revenue (ttm)	19.49B
Revenue Per Share (ttm)	67.47
Gross Profit (ttm)	8.06B
EBITDA (ttm)³	4.25B
Net Income Avi to Common (ttm)	1.22B
Diluted EPS (ttm)	4.22

Share Statistics

Beta (5Y Monthly)	0.43
52-Week Change	-10.33%
S&P500 52-Week Change	23.99%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	288.90M
Dividend Yield	1.62%
Float ⁴	288.01M
% Held by Insiders	0.31%
% Held by Institutions	86.97%

Balance Sheet

Total Cash (mrq)	1.24B
Total Cash Per Share (mrq)	4.28
Total Debt (mrq)	16.11B
Total Debt/Equity (mrq)	63.60%
Current Ratio (mrq)	1.08%
Quick Ratio (mrq)	0.64%
Book Value Per Share (mrq)	87.68

Cash Flow

Operating Cash Flow Per Share (ytd)	2.93
Free Cash Flow (ytd)	739.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Becton Dickinson & Co.

Trade With A Regulated Broker